Jim Biagi

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Amit M. Oza, Laurie Elit, Ming‐Sound Tsao et al. · Journal of Clinical Oncology · 2011 · 333 citations · Full text

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 254 citations · Full text

Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148

Amit M. Oza, Elizabeth A. Eisenhauer, Laurie Elit et al. · Journal of Clinical Oncology · 2008 · 141 citations · Full text

A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia

Iván Díaz-Padilla, Michelle Wilson, Blaise Clarke et al. · Gynecologic Oncology · 2015 · 79 citations

Single-agent Ro4929097, Oncology, Medicine +8

Increased Incidence of Ventricular Arrhythmias in Patients With Advanced Cancer and Implantable Cardioverter-Defibrillators

Andrés Enríquez, Jim Biagi, Damian Redfearn et al. · JACC. Clinical electrophysiology · 2016 · 50 citations

Advanced Cancer, Heart Failure, Ventricular Arrhythmias +12